Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL-Reference-Cited by-同舟云学术

Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL

Published:2019-01-28 Issue:3 Volume:15 Page:232-240
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Schmidl Christian^ORCID,Vladimer Gregory I.^ORCID,Rendeiro André F.^ORCID,Schnabl Susanne,Krausgruber Thomas,Taubert Christina^ORCID,Krall Nikolaus,Pemovska Tea^ORCID,Araghi Mohammad,Snijder Berend,Hubmann Rainer,Ringler Anna,Runggatscher Kathrin,Demirtas Dita,de la Fuente Oscar Lopez,Hilgarth Martin,Skrabs Cathrin,Porpaczy Edit,Gruber Michaela,Hoermann Gregor,Kubicek Stefan^ORCID,Staber Philipp B.,Shehata Medhat,Superti-Furga Giulio^ORCID,Jäger Ulrich,Bock Christoph^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/s41589-018-0205-2.pdf

Reference48 articles.

1. Woyach, J. A., Johnson, A. J. & Byrd, J. C. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120, 1175–1184 (2012).

2. Stevenson, F. K., Krysov, S., Davies, A. J., Steele, A. J. & Packham, G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 118, 4313–4320 (2011).

3. Burger, J. A. & Chiorazzi, N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 34, 592–601 (2013).

4. Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32–42 (2013).

5. O’Brien, S. et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet. Oncol. 17, 1409–1418 (2016).

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancer-driven gene regulatory networks inference from single-cell RNA-seq and ATAC-seq data;Briefings in Bioinformatics;2024-07-25

2. Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature;Acta Haematologica;2024-02-24

3. Biological, prognostic, and therapeutic impact of the epigenome in CLL;Seminars in Hematology;2023-12

4. Standardized assays to monitor drug sensitivity in hematologic cancers;Cell Death Discovery;2023-12-01

5. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia;Blood;2023-04-06